Adam J. Townsend - 12 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Commercial Officer
Signature: /s/ David Watson, attorney-in-fact for Adam Townsend
Issuer symbol: APLS
Transactions as of: 12 Jan 2023
Net transactions value: +$2,274,017
Form type: 4
Filing time: 17 Jan 2023, 18:44:16 UTC
Previous filing: 05 Jan 2023
Next filing: 24 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+27,488	+64%	$0.000000	70,395	12 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$2,274,017	+43,183		$52.66	43,183	12 Jan 2023	Common Stock	43,183	$52.66	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a Restricted Stock Unit award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.
F2	This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.